MY150747A - Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer - Google Patents

Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Info

Publication number
MY150747A
MY150747A MYPI20094194A MY150747A MY 150747 A MY150747 A MY 150747A MY PI20094194 A MYPI20094194 A MY PI20094194A MY 150747 A MY150747 A MY 150747A
Authority
MY
Malaysia
Prior art keywords
compounds
cancer
treatment
pi3k
pyrido
Prior art date
Application number
Other languages
English (en)
Inventor
Chris A Buhr
Wang Longcheng
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MY150747A publication Critical patent/MY150747A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI20094194 2007-04-11 2008-04-11 Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer MY150747A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
MY150747A true MY150747A (en) 2014-02-28

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20094194 MY150747A (en) 2007-04-11 2008-04-11 Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Country Status (25)

Country Link
US (2) US20100209340A1 (OSRAM)
EP (1) EP2142544B8 (OSRAM)
JP (1) JP2010523681A (OSRAM)
KR (1) KR20090130104A (OSRAM)
CN (1) CN101711249A (OSRAM)
AU (1) AU2008239596B2 (OSRAM)
BR (1) BRPI0810175A2 (OSRAM)
CA (1) CA2683820A1 (OSRAM)
CO (1) CO6241119A2 (OSRAM)
CR (1) CR11098A (OSRAM)
DO (1) DOP2009000242A (OSRAM)
EA (1) EA018964B1 (OSRAM)
EC (1) ECSP099722A (OSRAM)
ES (1) ES2425068T3 (OSRAM)
IL (1) IL201209A0 (OSRAM)
MA (1) MA31336B1 (OSRAM)
MX (1) MX2009010815A (OSRAM)
MY (1) MY150747A (OSRAM)
NI (1) NI200900183A (OSRAM)
NZ (1) NZ579945A (OSRAM)
SV (1) SV2009003389A (OSRAM)
TN (1) TN2009000389A1 (OSRAM)
UA (1) UA101315C2 (OSRAM)
WO (1) WO2008127712A1 (OSRAM)
ZA (1) ZA200906648B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828186A1 (en) * 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
HRP20110621T2 (hr) 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
ES2430614T3 (es) 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
EP2142543B8 (en) * 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
EP2350070A1 (en) * 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
CA2785499C (en) * 2009-12-22 2017-05-02 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
AU2012332486A1 (en) 2011-11-01 2014-06-19 Arthur Decillis N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
DE602005002562T2 (de) * 2004-05-04 2008-01-31 Warner-Lambert Company Llc Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
JP5480503B2 (ja) * 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
ATE539752T1 (de) * 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
HRP20110621T2 (hr) * 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3

Also Published As

Publication number Publication date
CN101711249A (zh) 2010-05-19
NZ579945A (en) 2012-05-25
SV2009003389A (es) 2010-04-27
EA200970936A1 (ru) 2010-02-26
UA101315C2 (ru) 2013-03-25
ECSP099722A (es) 2009-12-28
KR20090130104A (ko) 2009-12-17
EP2142544B8 (en) 2013-07-03
CA2683820A1 (en) 2008-10-23
TN2009000389A1 (en) 2010-12-31
US20130343988A1 (en) 2013-12-26
ZA200906648B (en) 2010-04-28
WO2008127712A1 (en) 2008-10-23
AU2008239596B2 (en) 2013-08-15
ES2425068T3 (es) 2013-10-11
EA018964B1 (ru) 2013-12-30
IL201209A0 (en) 2010-05-31
NI200900183A (es) 2010-10-05
JP2010523681A (ja) 2010-07-15
US20100209340A1 (en) 2010-08-19
CR11098A (es) 2010-01-27
EP2142544B1 (en) 2013-05-22
MX2009010815A (es) 2009-10-29
BRPI0810175A2 (pt) 2014-12-30
MA31336B1 (fr) 2010-04-01
DOP2009000242A (es) 2010-04-30
CO6241119A2 (es) 2011-01-20
AU2008239596A1 (en) 2008-10-23
HK1139941A1 (en) 2010-09-30
EP2142544A1 (en) 2010-01-13

Similar Documents

Publication Publication Date Title
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
IL260127B (en) mek inhibitors and methods of using them
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2009009786A (es) Inhibidores de la via de hedgehog.
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MX2010007746A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis.
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
TW200606162A (en) Pyrazolopyridine derivatives
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2007146124A3 (en) Deuterated tadalafil derivatives
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
TW200745102A (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof